I wonder what changed, as they are reporting higher SVR rates in this trial?
Looks like the 2014 report relates to earlier trials for approval for use in US so probably consisted mostly of western patient profile whereas these latest late stage trial results are for an all Chinese patient profile. This differing result is possibly to be expected as various racial groupings show differing responses to the old interferon treatments and also susceptibility to fibrosis/cirrhosis.
G3a since '78 - Dx '12 - F4 (2xHCC)
24wk Tx - PEG/Riba/Dac 2013 relapsed
24wk Tx - Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx - 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 - 22/06/17 UND
SRV12 - 27/07/17 UND
SVR24 - 26/10/17 UND
ABBVIE RECEIVES CHMP POSITIVE OPINION FOR VIEKIRAX® (OMBITASVIR/PARITAPREVIR/RITONAVIR TABLETS) + EXVIERA® (DASABUVIR TABLETS) WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN GENOTYPE 1B:
Quoted from the above article. Steve Miller, chief medical officer of Express Scripts wrote:
"The U.S. is 4.6 percent of the world's population, we're 32 percent of the world's drug revenue, and we're somewhere between 50 and 70 percent of world drug profitability," Miller said. "The United States has been spending money to protect the world for decades. We're now being asked to essentially fund all pharmaceutical drug development. ... We cannot continue to carry this burden."